Diabetes mellitus in Asia accounts for more than half of the global prevalence. There is a high prevalence of cardiovascular disease (CVD) in the region among people with type 2 diabetes mellitus (T2DM) and it is often associated with multiple risk factors including hypertension, renal disease and obesity. The early onset of T2DM and the eventual long disease duration portends an increasing proportion of the population to premature CVD. In addition to lowering blood glucose, sodium-glucose co-transporter-2 (SGLT-2) inhibitors exert favourable effects on multiple risk factors (including blood pressure, body weight and renal function) and provide an opportunity to reduce the risk of CVD in patients with T2DM. In this article, we consolidated the existing literature on SGLT-2 inhibitor use in Asian patients with T2DM and established contemporary guidance for clinicians. We extensively reviewed recommendations from international and regional guidelines, published data from clinical trials in the Asian population (dapagliflozin, canagliflozin, empagliflozin, ipragliflozin, luseogliflozin and tofogliflozin), CVD outcomes trials (EMPAREG-OUTCOME, CAN-VAS and DECLARE-TIMI 58) and real-world evidence studies (CVD-REAL, EASEL, CVD-REAL 2 and OBSERVE-4D). A series of clinical recommendations on the use of SGLT-2 inhibitors in Asian patients with T2DM was deliberated among experts with multiple rounds of review and voting. Based on the available evidence, we conclude that SGLT-2 inhibitors represent an evidence-based therapeutic option for the primary prevention of heart failure hospitalization and secondary prevention of CVD in patients with T2DM, and should be considered early on in the treatment algorithm for patients with multiple risk factors, or those with established CVD. K E Y W O R D S cardiovascular, diabetes, gliflozins, sodium-glucose co-transporter-2 inhibitors, type 2 diabetes mellitus
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| INTRODUCTION
Cardiovascular disease (CVD) is the most common cause of death globally, 1 and patients with type 2 diabetes mellitus (T2DM) have a 2-to 3-fold increased risk of CVD. 2, 3 T2DM is also one of the major causes of premature mortality besides CVD, cancer and chronic pulmonary diseases. 4 About 40% of deaths in patients with T2DM are attributed to CVD. In addition, there is a high incidence of non-fatal cardiovascular (CV) events in patients with T2DM, with heart failure (HF) hospitalizations accounting for up to 33% of non-fatal CV events. [5] [6] [7] [8] The high prevalence of T2DM in Asia will lead to an epidemic of CVD and HF, thus prevention of CV complications is of great importance in managing patients with T2DM. 9 Despite the close link between hyperglycaemia and CV complications, the effects of intensive glucose lowering on reducing CV outcomes remain inconclusive. [10] [11] [12] Early intensive glucose lowering among newly diagnosed T2DM may have a legacy effect that is only translated into CV benefits 10 to 20 years later. 13 Among patients with long-term T2DM with high risk of CVD, intensive glucose lowering has not shown benefits on CV outcomes and could be harmful. [10] [11] [12] Patients with T2DM have concomitant multiple risk factors for CVD, such as high blood pressure (BP), dyslipidaemia and albuminuria.
To this end, control of multiple risk factors has been shown to confer CV protection. 9, 14, 15 In the Steno-2 study, multifactorial management of hyperglycaemia, hypertension, hyperlipidaemia and microalbuminuria halved the risk of CV morbidity and mortality in patients with T2DM. 16, 17 A glucose-lowering drug (GLD) with multifactorial effects on CV risk factors has long been desired but not forthcoming, with none of the GLDs showing definitive CV protective effects in T2DM.
Traditionally, GLDs are designed primarily to improve hyperglycaemia; however, following the observation of increased risk of myocardial infarction (MI) with rosiglitazone in patients with T2DM, all new GLDs are required to show non-inferiority against placebo for the risk of major adverse cardiac events (MACE) in an adequately powered cardiovascular outcomes trial (CVOT) in high-risk T2DM patients. For example, the CVOTs of dipeptidyl peptidase-4 inhibitors showed noninferiority against placebo for the risk of MACE, but a signal for higher HF hospitalizations was observed with saxagliptin and alogliptin. 18, 19 Conversely, four large CVOTs of sodium-glucose co-transporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) analogues showed significant benefits on different types of CV outcomes depending on the trial populations and mode of action of the drugs: empagliflozin (EMPA-REG Outcome trial, 2015), 6 liraglutide (LEADER trial, 2016), 8 canagliflozin (CANVAS trials, 2017) 7 and dapagliflozin (DECLARE- TIMI 58) . 20 A meta-analysis of three CVOTs of SGLT-2 inhibitors showed a significant reduction in MACE and hospitalization for HF, and delayed the progression of renal complications among patients with T2DM with multiple risk factors or established CVD. 21 The findings are corroborated by several real-world evidence studies comprising over 1.5 million patients with T2DM that reported a significant reduction in CV outcomes with the use of SGLT-2 inhibitors, [22] [23] [24] [25] suggesting a potential class effect. In the recently completed CRE-DENCE trial, the SGLT-2 inhibitor canagliflozin significantly reduced the risk of disease progression (a composite of end stage renal disease (ESRD), doubling of the serum creatinine level from baseline for at least 30 days, or death from renal or CV disease) by 30% in patients with diabetic kidney disease. 26 Compared with GLP-1 analogues, SGLT-2 inhibitors exhibit additional benefits, including reduced risk of HF hospitalizations, favourable tolerability profile, insulin-independent glucose-lowering effects and once-daily oral administration. Given the epidemic of T2DM and CVD in Asia, a group of experts curated, reviewed and consolidated the current literature on SGLT-2 inhibitors in this population to produce a series of clinical recommendations on their clinical use. May 15, 2018 , using the search terms "canagliflozin" OR "dapagliflozin" OR "empagliflozin" OR "ipragliflozin" OR "luseogliflozin" OR "tofogliflozin" AND "type 2 diabetes." A list of studies and reviews were screened for efficacy and safety studies of SGLT-2 inhibitors conducted in Asia. The panel also critically analyzed recommendations from international guidelines, as well as results from CVOTs and realworld evidence studies. Following discussion, the panel reached consensus on a series of recommendations supported by scientific evidence and experts' clinical opinions.
| METHODOLOGY

| EPIDEMIOLOGY AND ASSOCIATED COMPLICATIONS OF T2DM IN ASIA
In 2017, the International Diabetes Federation (IDF) estimated that 158.8 million (9.5%) and 82 million (8.5%) adults aged 20 to 79 years in the western Pacific and south-east Asia regions have diabetes, respectively, 27 accounting for 56.7% of the global prevalence. China has the largest affected population (114.4 million) followed by India (72.9 million), with over 90% of them affected by T2DM. 9 By 2045, the population with diabetes is expected to increase by 22% in the western Pacific to 193.3 million (prevalence: 10.3%) and by 85% in south-east Asia to 151.4 million (prevalence: 11.1%). 27 Furthermore, more than half of the patients with T2DM remain undiagnosed (57.6% in south-east Asia and 54% in the western Pacific). 27 In the Global Burden of Disease study, CVD in the east, south and south-east Asia regions and the high-income Asia Pacific countries (Brunei, Japan, South Korea and Singapore) accounted for~50% of the global burden, with a total of 210 million people having CVD. 28 Alarmingly, there is a high prevalence of HF in the Asian countries (ranging from 1.3 to 6.7%), with rates rising to >30% among the elderly (aged ≥70 years). 29, 30 The coexistence of multiple risk factors leads to premature CV morbidity and mortality in patients with T2DM. Individuals without hypertension, obesity and diabetes were found to have up to 85% lower risk of incident HF and lived 3 to 15 years longer free of HF compared with those with one, two or all three risk factors. 31 According to IDF estimates, 47 per 1000 patients with T2DM experience a CV event every year. 32 In the recent CVOTs in patients with T2DM, CV deaths accounted for 60% to 74% of total deaths while HF hospitalizations accounted for up to 33% of non-fatal CV events. [5] [6] [7] [8] Asian patients with T2DM also have a higher prevalence of ischaemic stroke and renal disease compared with their European counterparts. 33 CVD and HF pose a huge burden on healthcare systems in Asian countries, [34] [35] [36] [37] thus there is an urgent need for the early detection and effective management of CV risk in patients with T2DM.
| ASIAN T2DM PHENOTYPE
Apart from interethnic differences in genetic predisposition, Asian patients with T2DM have several distinctive features compared with their Caucasian counterparts. Asian populations have a high prevalence of young-onset diabetes, 38, 39 metabolic syndrome, β-cell dysfunction, 40 and a higher degree of insulin resistance (particularly in south Asians). [41] [42] [43] They also have lower lean muscle mass, higher visceral fat mass, lower circulating adiponectin levels, [44] [45] [46] and are more likely to exhibit postprandial hyperglycaemia. 47, 48 East Asian populations (in China, Korea and Japan) also have reduced insulin response to metabolic stress such as obesity. 41, [49] [50] [51] In south Asian populations (in India), undernutrition or overnutrition in utero (pregnant mothers with diabetes) or during infancy increases the risk of impaired glucose tolerance or diabetes in young adulthood. Exposure to poor nutrition in utero or during infancy may lead to foetal programming that promotes fat preservation. In these predisposed individuals, positive energy balance later in life results in accelerated accumulation of adiposity with increased insulin resistance and β-cell dysfunction. 52 In the Joint Asia Diabetes Evaluation (JADE) register,~18% of Asian patients with T2DM were diagnosed before the age of 40 years (vs 13.8% in the USA population aged 18-44 years 53 ), with a mean age of 32.2 years at diagnosis. 38 Compared with late-onset disease, T2DM diagnosed before the age of 40 years is associated with a higher risk of CVD, which is attributed to the longer duration of disease. 54 
| SGLT-2 INHIBITORS
Most of the plasma glucose (99%) filtered through the glomerulus is reabsorbed through SGLT in the luminal membrane of proximal renal tubules. Two distinct isoforms of SGLT have been identified. The lowcapacity, high-affinity SGLT-1 transporters are found in various tissues, including the small intestine, heart, skeletal muscle and kidney. The highcapacity, low-affinity SGLT-2 transporters are located almost exclusively in the kidney and are responsible for 90% of the glucose reabsorption from the S1 and S2 segments of the proximal convoluted tubule. SGLT-2 inhibitors reduce blood glucose through selective and reversible inhibition of the SGLT-2, thereby preventing the renal reabsorption of glucose and increasing its urinary excretion, 55,56 a mechanism independent of β-cell function and insulin resistance. Also, SGLT-2 inhibitors have favourable effects on multiple risk factors such as BP, body weight and insulin sensitivity. [55] [56] [57] The reduction in body weight with SGLT-2 inhibitors is comparable with that observed with GLP-1 analogues. 58 In most Asian countries, four SGLT-2 inhibitors (canagliflozin, dapagliflozin, empagliflozin and luseogliflozin) have been approved for clinical use in patients with T2DM while additional agents such as ipragliflozin and tofogliflozin have been approved in Japan (Table 1) . with other glucose-lowering therapies. [59] [60] [61] [62] The guidelines also recommend SGLT-2 inhibitors as an acceptable alternative to metformin as initial therapy when metformin is contraindicated or not tolerated.
Similar recommendations have been made in clinical practice guidelines for T2DM in Asian countries. [63] [64] [65] In 2019, the American Diabetes Association (ADA) Standard of Care provided a treatment algorithm based on the presence of established CVD or chronic kidney disease (CKD). 66 In patients with predominant atherosclerotic CVD, GLP-1 analogues or SGLT-2 inhibitors are recommended as add-on therapy to metformin. In patients with predominant HF or CKD, an SGLT-2 inhibitor is the recommended therapy after metformin. 66 The 2016 European Society of Cardiology (ESC) guidelines for CVD prevention recommend that SGLT-2 inhibitors should be considered early on in the clinical course to reduce all-cause and CV death in patients with T2DM and CVD (Class IIa recommendation). 67 The 2016 ESC guidelines for the management of chronic HF recommend that empagliflozin should be considered in patients with T2DM to prevent or delay the onset of HF and to prolong survival (Class IIa recommendation). 68 It should be noted that these guidelines require an update following the availability of evidence from the CANVAS and DECLARE-TIMI 58 trials. The more recent Canadian practice guidelines recommend the addition of SGLT-2 inhibitors to reduce the risk of major CV events, HF hospitalization, and progression of nephropathy in patients with T2DM. 69 from baseline, with a greater reduction observed in patients with high baseline HbA1c levels. [72] [73] [74] [75] [76] [77] In Asian patients with uncontrolled T2DM, SGLT-2 inhibitors as add-on therapy to other GLDs further reduced HbA1c, ranging from −0.44% to −1.26% (study duration up to 52 weeks). [78] [79] [80] [81] [82] [83] In insulin-treated patients, SGLT-2 inhibitors reduced HbA1c, ranging from −0.55% to −1.09%, and led to insulin dose reductions (study duration up to 52 weeks). 84-88
| Safety
SGLT-2 inhibitors are well tolerated, with low risk of hypoglycaemia, even when combined with other oral GLDs. In insulin-treated Asian patients, most SGLT-2 inhibitors increased the risk of hypoglycaemia, except for dapagliflozin, which was not associated with increased risk of hypoglycaemia compared with placebo. [84] [85] [86] [87] [88] [89] [90] [91] The most common adverse event (AE) reported with SGLT-2 inhibitors is mycotic genital infections, which can be managed with standard treatment and good personal hygiene. In addition, urinary tract infections and volume depletion-related AEs (especially in patients with impaired renal function, elderly patients, and those receiving diuretics) have also been reported. [89] [90] [91] A higher risk of euglycaemic diabetic ketoacidosis (DKA) was observed with SGLT-2 inhibitors, albeit with a very low overall event rate. 92 The risk of euglycaemic DKA can be minimized through patient education and by avoiding trigger situations, such as a very low carbohydrate diet or excessive alcohol intake, and suspension of insulin treatment. SGLT-2 inhibitors should be discontinued at least 24 hours before metabolically stressful events such as scheduled surgeries or extreme sports. 92 itors. 55, 56 In Asian patients with T2DM, several studies have reported the beneficial metabolic and vascular effects of SGLT-2 inhibitors. In the following sections, we summarize these clinical benefits in Asian studies, as well as data from CVOTs and real-world evidence studies.
| Effect on glycaemic variables
Apart from HbA1c, indices of insulin resistance and hyperinsulinaemia are associated with impaired myocardial contractility, cardiac hypertrophy and atherosclerosis 93, 94 ; an association of postprandial hyperglycaemia with oxidative stress and endothelial dysfunction has also been reported. 95 In Asian patients with T2DM, SGLT-2 inhibitors alone or in combination with oral GLDs improved insulin sensitivity and β-cell function, reduced insulin and proinsulin levels, and decreased postprandial glucose levels. 72 SGLT-2 inhibitors reduce systolic BP by~3 to 5 mmHg and diastolic BP by~2 to 3 mmHg, 98 with similar findings for 24-hour systolic and diastolic BP and pulse pressure. 99, 100 In Asian patients with T2DM, similar reductions in systolic and diastolic BP have been reported (range: SBP, −1.2 to −7.9 mmHg; DBP, −0.8 to −6.1 mmHg; Table S2 ). The exact mechanism of BP lowering by SGLT-2 inhibitors is probably related to the osmotic diuretic and mild natriuretic effects. 55 In addition, empagliflozin and dapagliflozin have been shown to reduce arterial stiffness and to improve vascular endothelial function, respectively, which may contribute to BP lowering. 101, 102 Arterial stiffness is associated with an increased risk of CV death, especially in patients with T2DM and those at high CV risk. 103 In a pooled analysis of five Phase III trials (duration up to 24 weeks) in patients with T2DM (N = 3300; 823 patients with hypertension), treatment with empagliflozin improved the markers of arterial stiffness (pulse pressure and arterial stiffness index) and vascular resistance (mean arterial pressure). 104 The DEFENCE study was a 16-week, prospective, randomized, open-label, parallel-group study designed to evaluate the effect of dapagliflozin on endothelial function, assessed by flow-mediated dilation (FMD), in Japanese patients with T2DM treated with metformin. 102 In patients with HbA1c ≥ 7%, treatment with dapagliflozin improved FMD with a mean (SD) change from baseline of 1.05% (2.59; P = 0.041). Notably, every 1% increase in FMD is associated with a 12% risk reduction in CV events. 105 
| Effect on body weight and fat mass
Asians have a higher visceral adiposity than Caucasians for the same body mass index. By inducing glycosuria, SGLT-2 inhibitors produce a calorie deficit with a net weight loss of 2 to 3 kg over 52 weeks of therapy, 98 with a similar effect in Asian populations (range: −1.29 to −3.9 kg; Table S2 ). Similarly, waist circumference, a marker for visceral adiposity, was reduced by SGLT-2 inhibitors (ranging from −1.2 to −3.8 cm; Table S2 ).
In a proof-of-concept study involving 27 obese Japanese patients with T2DM, treatment with dapagliflozin (5 mg) increased adiponectin, ketone bodies, and reduced high-sensitivity C-reactive protein (CRP) levels. 106 The increase in adiponectin levels correlated with reductions in HbA1c and body weight, supporting the benefits of SGLT-2 inhibitors for adipocyte biology.
In epidemiological surveys, epicardial fat volume (EFV) is shown to be positively correlated with the risk of atherosclerosis and coronary events. 107, 108 In Japanese patients with T2DM with or without obesity, ipragliflozin and luseogliflozin reduced EFV (measured by magnetic resonance imaging) at 12 weeks (change from baseline: luseogliflozin, 6 cm 3 , P = 0.048; ipragliflozin, 13 cm 3 ; P = 0.008), 109, 110 which correlated with reduction in circulating CRP levels. 110 
| Effect on lipids
As in Caucasians, treatment with SGLT-2 inhibitors increased highdensity lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C), and reduced triglyceride levels among Asian patients with T2DM (Table S2) 
| Effect on haematocrit
Haematocrit is an independent predictor of CVD, and the risk of CVD follows a U-shaped relationship with an increased risk at the lowest and highest quartiles of haematocrit. 112, 113 In the EMPA-REG OUT-COME trial, changes in haematocrit and haemoglobin were the most important mediators of CV death risk reduction in an exploratory analysis (mediating 51.8% and 48.9%, respectively, of the effect of empagliflozin vs placebo on the risk of CV death). 114 In Asian patients with T2DM, SGLT-2 inhibitor treatment has been shown to increase haematocrit (ranging from +0.59% to +5.5%; Table S2 ). In a metaanalysis of 25 randomized controlled trials, treatment with SGLT-2 inhibitors was associated with an increase in haematocrit by 1.4%
(95% CI, 0.2-2.7; P < 0.05 vs placebo). 115 Possible mechanisms of this effect include enhancement of erythropoiesis via increased production of erythropoietin (through a reduction in the workload of the proximal tubules and restoration of tubulointerstitial function) and
haemoconcentration (secondary to diuresis). 116 7.6 | Effect on CV outcomes Three CVOTs have now confirmed the CV benefits of SGLT-2 inhibitors (empagliflozin, canagliflozin and dapagliflozin) in patients with T2DM with established CVD on optimal therapy or those with multiple risk factors. 6, 7, 20 In a meta-analysis of these trials, which included 0.61-0.79; P < 0.0001) irrespective of history of HF (P for interaction = 0.76). 21 Table 2 summarizes the results from these three CVOTs. 6, 7, 20 In the EMPA-REG OUTCOME trial, which recruited adults (N = 7020) with T2DM and established CVD receiving standard care, 6 after a median follow-up of 3.1 years, treatment with empagliflozin (10 or 25 mg once daily) significantly reduced the relative risk of primary endpoint three-point MACE by 14% (P = 0.04 for superiority) and
CV death by 38% (P < 0.001) compared with placebo. However, there was no significant between-group difference for the risk of non-fatal MI and non-fatal stroke, indicating that the risk reduction in MACE was driven primarily by the reduction in CV death. Treatment with empagliflozin also reduced the risk of HF hospitalizations by 35% (P = 0.002) and all-cause death by 32% (HR 0.68, 95% CI: 0.57-0.82; P < 0.001) although there was no significant between-group difference for the secondary outcomes of a four-point MACE, including hospitalization for unstable angina (HR 0.89, 95% CI: 0.78-1.01; P < 0.001 for non-inferiority; P = 0.08 for superiority). 6 In a subgroup analysis of Asian patients (N = 1517), consistent results were found, with reduced risk of the primary outcome in the empagliflozin group with no heterogeneity in treatment effect by race (HR 0.68, 95% CI: 0.48-0.95; Pvalue for the interaction of treatment effect by race = 0.0872). 117 The CANVAS programme integrated data from two trials (CANVAS and CANVAS-Renal), which recruited 10 142 participants with T2DM and high CV risk. 7 The mean follow-up period for the pooled analysis was 188.2 weeks (295.9 weeks in CANVAS and 108.0 weeks in CANVAS-R). In a prespecified analysis, canagliflozin consistently reduced the risk of MACE in patients with or without a history of CVD for both primary and secondary prevention (interaction P = 0.18). 118 The DECLARE-TIMI 58 was the largest of the three SGLT-2 inhibitor CVOTs, which recruited 17 160 patients with T2DM with or without atherosclerotic CVD (6974 with CVD and 10 186 with multiple risk factors for CVD), with a median follow-up duration of 4.2 years. 20 In the primary safety outcome analysis, dapagliflozin met the prespecified criterion for non-inferiority to placebo with respect to MACE (P < 0.001 for non-inferiority F I G U R E 1 Pleiotropic effects of sodium-glucose co-transporter-2 (SGLT-2) inhibitors. BP, blood pressure; NHE1, sodiumhydrogen exchanger 1; NHE3, sodium-hydrogen exchanger 3; RAAS, renin-angiotensin aldosterone system stage renal disease, or death from renal or CV cause) was reduced with dapagliflozin, compared with placebo (HR 0.76, 95% CI: 0.67-0.87). 20 In addition to the CVOTs, four large real-world studies have reported the CV outcomes of SGLT-2 inhibitors in patients with T2DM (Table 3) . [22] [23] [24] [25] In the Comparative Effectiveness of Cardiovascular Outcomes (CVD-REAL), the Evidence for cArdiovascular outcomes with Sodium-glucose co-transporter 2 inhibitors in the rEal worLd (EASEL), and the OBSERVE-4D studies, the risk of HF hospitalization was significantly reduced by up to 61% with SGLT-2 inhibitors compared with other non-SGLT-2 inhibitor GLDs. [23] [24] [25] The CVD-REAL 2 study (real-world data) evaluated CV outcomes in propensity-matched patients with T2DM from the Asia-Pacific (South Korea, Japan, Singapore and Australia), Middle East (Israel) and North American (Canada) regions, who initiated treatment with SGLT-2 inhibitors or other oral GLDs (470 128 instances of treatment initiation in 408 807 patients). 22 Results from Asian countries (South Korea, Japan and Singapore) showed that treatment with SGLT-2 inhibitors was associated with a significant reduction in the risk of all-cause death (by 25%-44%), HF hospitalization (13%-38%), MI (19%-25%) and stroke (18%-66%) compared with other oral GLDs. 22 The current prevalence rates of T2DM and CVD and the estimated future risk are alarmingly high in Asia; this calls for effective measures directed towards prevention of disease onset and effective management of T2DM and CV disease.
| POTENTIAL MECHANISMS MEDIATING THE CARDIORENAL BENEFITS OF SGLT-2 INHIBITORS
Glycaemic efficacy of SGLT-2 inhibitors in Asian patients with T2DM
2
The glycaemic efficacy (HbA1c reduction) of SGLT-2 inhibitors in Asian patients with T2DM is consistent with that reported in Caucasian populations; SGLT-2 inhibitors are equally effective as a monotherapy or in combination with other oral GLDs.
3
The glycaemic efficacy of SGLT-2 inhibitors is consistent across subgroups, including gender, age, race, duration of disease and baseline BMI.
Safety and tolerability of SGLT-2 inhibitors in Asian patients with T2DM
4
The risk of hypoglycaemia is low with SGLT-2 inhibitors when used as monotherapy or in combination with other oral GLDs. The risk of hypoglycaemia should be monitored when SGLT-2 inhibitors are used in combination with insulin. SGLT-2 inhibitors have insulin-sparing effects; adjustment of the insulin dose may be required.
5
SGLT-2 inhibitors may increase the risk of mycotic genital infections (that can be managed with standard treatment and maintenance of perineal hygiene), bacterial urinary tract infections, and euglycaemic DKA (treatment with SGLT-2 inhibitors should be discontinued at least 24 h before metabolically stressful events such as scheduled surgeries or extreme sports).
6
As a result of diuretic and mild natriuretic effects, SGLT-2 inhibitors may cause intravascular volume contraction; there is a risk of volume contraction-related AEs (such as symptomatic hypotension, dizziness, acute kidney disease), especially in patients with impaired renal function, elderly patients, and those receiving diuretics.
7
An increased risk of bone fractures and lower limb amputations is reported only with canagliflozin in the CANVAS trial.
Use in special populations 8
Elderly: No dosage adjustments are required in elderly patients; the risk of volume depletion-related AEs, renal impairment or urinary tract infection is higher in patients aged ≥65 y.
9
Risk of euglycaemic DKA is higher in lean patients, those with reduced β-cell reserves, and those receiving a ketogenic diet.
10
Ramadan: No dose adjustments are required; move dose timing to the post sunset (evening) meal.
Non-glycaemic metabolic effects of SGLT-2 inhibitors
11
Treatment with SGLT-2 inhibitors is associated with clinically relevant reductions in BP and arterial stiffness, improvement in endothelial function, and an increase in haematocrit.
12
SGLT-2 inhibitors are associated with a reduction in body weight, visceral adiposity and atherogenic small dense LDL-C, an increase in HDL-C, and less atherogenic large buoyant LDL-C.
Effects on CV outcomes
13
SGLT-2 inhibitors are recommended for use in patients with T2DM with multiple risk factors to prevent and reduce hospitalization for HF.
14 SGLT-2 inhibitors are recommended for use in patients with T2DM with established CV disease to reduce the risk of CV death.
15
The CV benefits of SGLT-2 inhibitors have been shown in multiple randomized controlled trials and real-world evidence studies, suggesting a class effect of SGLT-2 inhibitors on CV outcomes.
Potential mechanism of CV effects
16
The beneficial CV effects of SGLT-2 inhibitors can be attributed to their impact on multiple risk factors, including a reduction in cardiac preload via diuresis and natriuresis, reduction in BP, body weight and visceral adiposity, shift in energy substrate from fat and glucose to ketone bodies, and an increase in haematocrit.
Place in the treatment algorithm for patients with T2DM
17
Considering their beneficial CV and metabolic effects, SGLT-2 inhibitors are the preferred second-line therapy after metformin for:
• The secondary prevention of CV events in patients with T2DM and established CV disease;
• The primary prevention of HF hospitalization events in patients with T2DM and multiple risk factors;
• The secondary prevention of HF hospitalization events in patients with T2DM and established CV disease.
Abbreviations: AE, adverse event; BMI, body mass index; BP, blood pressure; CV, cardiovascular; DKA, diabetic ketoacidosis; GLD, glucose-lowering drug; HDL-C, high-density lipoprotein cholesterol; HF, heart failure; LDL-C, low-density lipoprotein cholesterol; SGLT-2, sodium-glucose co-transporter-2; T2DM, type 2 diabetes mellitus. and the kidneys (NHE3 isoform), which are implicated in sodium retention, cardiac hypertrophy, injury, fibrosis (leading to the progression of HF) and pathogenesis of diabetic nephropathy. 55 inhibition in patients with HF, CKD and hypertension, and these will define the place of SGLT-2 inhibitors in CV disease management.
Here are some of the large, ongoing outcome trials with SGLT-2 inhibitors:
• Heart failure: EMPEROR-Reduced (empagliflozin; NCT03057977); EMPEROR-Preserved (empagliflozin; NCT03057951); Dapa-HF (dapagliflozin; NCT03036124); DELIVER (dapagliflozin; NCT036 19213);
• Diabetic nephropathy: Dapa-CKD (dapagliflozin; NCT03036150);
EMPA-KIDNEY (empagliflozin; NCT03594110);
• Hypertension/prehypertension: PREHYPD (empagliflozin; NCT01 001962).
Also, there are several ongoing studies to determine the mechanisms of CV and renal benefits with SGLT-2 inhibitors (Figure 2 ).
These include studies evaluating the effects of SGLT-2 inhibitors on heart function and metabolism, energy metabolism and fuel handling, endothelial function and vascular compliance, kidney function, and metabolic regulation of fluid and sodium balance. Furthermore, SGLT-2 inhibitors have been shown to reduce the liver fat content in randomized and open-label studies and may provide liver protection in patients with non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). 122 The effects of SGLT-2 inhibitors in patients with NAFLD and those at risk of NASH remain to be confirmed in long-term randomized controlled studies.
| CONCLUSIONS AND RECOMMENDATIONS
With the increasing prevalence of T2DM and heightened risk of CVD in Asia, SGLT-2 inhibitors represent a novel, key therapeutic agent for clinicians in the management of patients with diabetes who have established CVD or who are at high risk of CV disease. Given their consistent benefits in the primary prevention of HF hospitalization and secondary prevention of CVD, SGLT-2 inhibitors should be considered early on in the treatment algorithm for patients with multiple risk factors or for those with established CVD. Based on the available evidence on SGLT-2 inhibitors in the Asian population, results from CVOTs as well as clinical experience, a series of clinical recommendations has been developed for the use of SGLT-2 inhibitors in this population (Table 4) . The ongoing mechanistic studies and other outcomes trials in patients with HF and CKD will eventually define the cardiorenal protective role of SGLT-2 inhibitors above and beyond glucose lowering. 
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